ELITE PHARMACEUTICALS INC /NV/ Quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD from Q1 2014 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary
Elite Pharmaceuticals Inc /Nv/ quarterly Deferred Tax Assets, Operating Loss Carryforwards history and growth rate from Q1 2014 to Q1 2024.
  • Elite Pharmaceuticals Inc /Nv/ Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending March 31, 2024 was $15.5M, a 11.8% decline year-over-year.
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q1 2024 $15.5M -$2.08M -11.8% Mar 31, 2024 10-K 2024-07-01
Q1 2023 $17.6M Mar 31, 2023 10-K 2024-07-01
Q1 2018 $19.2M -$10.7M -35.8% Mar 31, 2018 10-K 2018-06-14
Q1 2017 $29.9M +$2.88M +10.7% Mar 31, 2017 10-K 2018-06-14
Q1 2016 $27M +$27M Mar 31, 2016 10-K 2018-06-14
Q1 2015 $24.5K* -$19.8M Mar 31, 2015 10-K 2017-06-14
Q1 2014 $19.8M Mar 31, 2014 10-K 2016-06-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.